Obsidian Therapeutics CEO Dr. Paul Wotton developed a novel solution to the workforce and resource disruption caused by COVID-19 social distancing restrictions. He’s made it available to other biotechs, cost-free. The Problem: When COVID-19 struck the United States hard and fast early this spring, few companies were prepared for the lock downs, the shutdowns, and the […]

Earlier this week, The US Food and Drug Administration (FDA) granted NeuroRx and Relief Therapeutics an Investigational New Drug (IND) permission to test their investigational therapy, RLF-100, for inhaled use in patients with moderate and severe coronavirus 2019 (COVID-19) in order to prevent progression to respiratory failure. RLF-100 contains Vasoactive Intestinal Polypeptide (VIP), a natural occurring peptide […]

ZURICH — The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 to prevent progression to respiratory failure, it and partner Relief Therapeutics Holdings said on Thursday. The clinical trial of the inhaled formulation of RLF-100 […]